Impact of Lutein, Zeaxanthin, and Fish Oil on Health
Official title: The Role of Lutein, Zeaxanthin, and Fish Oil on Cognitive Function and Bone Health in Healthy Adults
Run by Texas A&M University · NCT06489873 · Data updated 2026-11-12
This study is testing if taking a daily supplement of lutein, zeaxanthin, and fish oil can help improve brain function, eye health, and bone strength in healthy adults aged 18-45 who have low eye pigment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Texas A&M University Academic / other |
| Locations | 1 site (College Station, Texas) |
| Status | Recruiting |
| Started | February 7, 2024 |
| Main results expected | May 1, 2026 |
| Study ends | May 1, 2026 |
| Registry record updated | September 30, 2025 |
| Trial ID | NCT06489873 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy adults aged 18-45 with a macular pigment optical density (MPOD) of less than 0.43.
✕Probably not a fit
Patients with allergies to lutein, zeaxanthin, or fish oil, or those with certain eye conditions or on specific medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of lutein, zeaxanthin, and fish oil (LZF) supplementation on cognitive performance, macular pigment optical density (MPOD), and bone health in healthy adults aged 18-45 with low MPOD. Participants will be randomly assigned to receive either the LZF supplement or a placebo daily for six months. The study aims to determine if LZF supplementation can significantly improve MPOD, cognitive performance, and bone density compared to controls. Assessments will include blood draws, MPOD measurements, DXA scans for bone health, and cognitive performance tests using Neurotracker software.
Why it matters
Potential benefit: If successful, this study could lead to improved cognitive function, enhanced visual health, and increased bone density in participants.
How similar studies have gone: Previous studies have shown promising results with similar supplementation approaches, indicating potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \<.43 MPOD, a self-reported best-corrected vision of 20/40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire. Exclusion Criteria: * allergic to lutein, zeaxanthin, or fish oil, taking supplements with \>6 mg lutein and/or \>2 mg zeaxanthin for more than two months before study starts, MPOD between \>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and/or taking neuroactive medications, such as Ritalin, Adderall, antidepressants, etc.
Where it's running
-
Gilchrist Building
College Station, Texas, United States Recruiting
Study contacts
- Principal investigator: Karen M Beathard, PhD — Texas A&M University
- Study coordinator: Karen M Beathard, PhD
- Email: karen-beathard@tamu.edu
- Phone: 979-220-2281
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding Age-Related Macular Degeneration and Its Progression
This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.
-
Blepharoptosis After Repeated Anti-VEGF Injections in One Eye
This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.
-
Short-Term Intensive PTSD Treatment for Military Personnel
This trial tests whether a brief, massed form of CPT and EMDR can quickly reduce PTSD symptoms and related cognitive problems in active-duty military personnel.
-
First-in-human test of ARO-033 in adults
This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.
-
Predicting Risk of AMD Progression Using Imaging in Aging Eyes
Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.
-
Does caffeine help professional chess players think faster and play better?
In this study, professional chess players try caffeinated versus decaffeinated coffee to see if caffeine improves focus, reaction time, and game performance.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.